XI’AN, CHINA--(Marketwire - August 14, 2012) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) (“Skystar” or the “Company”), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2011 earnings, for the period ended June 30, 2011.
Second Quarter 2012 Highlights
- Revenue decrease slightly 2.5% YoY to $8.9 million
- Micro-organism products totaled $4.0 million, up 102.0% YoY
- Veterinary medicines totaled $2.5 million, a decrease of 61.2% YoY
- Feed additives totaled $1.3 million, up 224.2% YoY
- Veterinary vaccines totaled $1.1 million, up 199.0% YoY
- Gross margin of 57.8% for the second quarter of fiscal 2011 as compared to 49.0% in the year ago period
- Net income of $1.7 million or $0.23 per fully diluted share, compared with net income of $1.5 million or $0.21 per fully diluted share in the year ago period
First Half 2012 Financial Highlights
- First half fiscal 2012 revenue increases 3.8% YoY to $16.8 million
- Gross margin of 56.0% for the first half of fiscal 2012 as compared to 49.8% in the year ago period
- Net income of $3.6 million or $0.48 per fully diluted share, compared with net income of $3.4 million or $0.48 per fully diluted share in the year ago period
Management Comments
Mr. Weibing Lu, Skystar Bio-Pharmaceutical’s chairman and chief executive officer, commented, “Skystar made significant progress in the second quarter of fiscal 2012 in its evolution to scale up its business. During the period, Skystar has been able to maintain fiscal profitability, control raw materials costs and operating expenses while moving forward with efforts to modernize and automate manufacturing of its veterinary vaccine, medication, probiotic and feed additives lines.
“In order to maintain revenue and profit in a ‘GMP certification’ year for several of Skystar’s production facilities, Management has ramped sales and marketing for other parts of the business and introduced various customer concession and retention programs to compensate for a reduced supply of veterinary medicine products and not have to reduce the price of products to customers.
“As previously announced on June 26, 2012, China’s Ministry of Agriculture (MOA) experts’ physically inspected the Company’s Huxian veterinary medicine manufacturing plant and published its recommendation to renew Skystar’s GMP certificate, valid for a period of five years. While the Company awaits post-inspection procedures from the MOA, the veterinary medicine plant in Huxian remains closed. Skystar anticipates the renewed GMP certificate will be physically received in the third quarter of 2012. During this time, the Company successfully shifted its sales strategy temporarily to other product lines, mainly probiotics and feed additives. The goal of this exercise was not only to maintain revenue guidance but to take the opportunity to further inroads in expanding the sales footprint of its probiotics line whose record sales doubled as compared to the same period a year ago.
“Operationally, the Compared pared back research and development activities, primarily moving forward with projects that were paid for already in previous years. As the GMP recertification at Huxian’s veterinary medicine facility heads closer towards full production the Company anticipates increasing efforts and investment in research and development at that juncture.
“Management is excited to share its results at the half year mark. Skystar has been able to successfully implement its operational strategy as it moves towards the most profitable half of the fiscal year. We believe that the course management has plotted will position Skystar to make forecasted fiscal guidance for 2012 and to position the Company for revamped growth in fiscal 2013,” concluded Mr. Lu.
Financial Summary
Skystar reported second quarter fiscal year 2012 revenues of $8,870,848 as compared to revenues of $9,096,141 for the comparable year ago period, a decrease of $225,293 or 2.5%. This was in line with management’s internal forecast due to there being no production at Huxian veterinary medication plant during the quarter for GMP re-examination.
Cost of revenue, which consists of raw materials, direct labor, and manufacturing overhead for our four product lines, was $3,746,938 for the three months ended June 30, 2012, as compared to $4,637,007 for the three months ended June 30, 2011, a decrease of $890,069 or 19.2%, as a result of decreased sales of our veterinary medications product line.
Gross profit was $5,123,910 for the three months ended June 30, 2012, a 15.0% year over year increase as compared to $4,459,134 for the three months ended June 30, 2011. Gross margin for the period was 58% due to selling higher margin products for the period.
Operating Expenses
Research and development costs totaled $330,532 for the three months ended June 30, 2012 as compared to $1,801,551 for the three months ended June 30, 2011, a decrease of $1,471,019 or 81.7%. The decrease was primarily due to less R&D efforts undertaken during the second quarter of 2012 as compared to the same period of 2011.
Selling expenses totaled $670,567 for the three months ended June 30, 2012 as compared to $609,826 for the three months ended June 30, 2011, an increase of $60,741 or 10.0%. This increase is primarily a result of increased shipping and handling costs related to delivering our products to customers as we continued to expand our market to remote areas, and to increased number of units to be shipped. Shipping and handling costs totaled $463,630 and $350,054 for the three months ended June 30, 2012 and 2011, respectively, an increase of $113,576 or 32.4%.
General and administrative expenses totaled $1,834,280 for the three months ended June 30, 2012 as compared to $515,293 for the three months ended June 30, 2011, an increase of $1,318,987 or 256.0%.
As of June 30, 2012, we had cash of $2,341,981. Our total current assets were $68,680,543, and our total current liabilities were $19,159,602, which resulted in a net working capital of $49,520,941.
Fiscal 2011 Guidance
We currently reiterate our fiscal 2012 guidance to be in the range of $53 million to $57 million for the full year.
Conference Call & Webcast Information
Skystar will host a conference call at 7:45 a.m. ET on Wednesday, August 15, 2012 to review the Company’s second quarter financial and operational performance. Mr. Weibing Lu, Skystar’s chairman and chief executive officer, will host the call, which will be webcast live.
Webcast
The webcast will be made available on the investor relations section of the Skystar corporate website at http://www.investorcalendar.com/IC/CEPage.asp?ID=169508.
Phone dial-in
Telephone access to the conference call will be available in North America by dialing +1 (877) 407-8031 or internationally by dialing +1 (201) 689-8031.
An audio replay of the conference call will be available approximately two hours following the conclusion of the call and for the following 30 day period. To access the replay in North America, dial +1 (877) 660-6853 or, when calling internationally, dial +1 (201) 612-7415, using replay account code # 286 and conference ID # 398886.
An archived replay of the conference webcast will also be available on investor relations section of the Skystar corporate website at http://www.skystarbio-pharmaceutical.com.
To be added to the Company’s email distribution for future news releases, please send your request to skystar@grayling.com.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the Company’s ability to receive timely certification and related government approvals, effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Financial Tables Follow
SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2012 2011 (Unaudited) -------------- -------------- ASSETS CURRENT ASSETS: Cash $ 2,341,981 $ 7,048,968 Accounts receivable, net of allowance for doubtful accounts of $542,888 and $438,678 as of June 30, 2012 and December 31, 2011, respectively 10,687,845 3,391,493 Inventories 13,277,963 14,851,159 Deposits, prepaid expenses and other receivables 2,772,002 3,421,487 Prepayments for raw materials purchasing 36,688,923 29,226,961 Loans receivable 2,911,829 964,088 -------------- -------------- Total current assets 68,680,543 58,904,156 -------------- -------------- PROPERTY, PLANT AND EQUIPMENT, NET 28,070,683 28,376,559 CONSTRUCTION-IN-PROGRESS 9,553,513 8,839,055 OTHER ASSETS: Long-term prepayments 1,207,154 1,512,817 Long-term prepayments for acquisitions 177,520 569,788 Intangible assets, net 5,513,494 5,674,206 -------------- -------------- Total other assets 6,898,168 7,756,811 -------------- -------------- Total assets $ 113,202,907 $ 103,876,581 ============== ============== LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 2,626,855 $ 1,047,067 Other payables and accrued expenses 5,039,774 5,274,598 Short-term loans 6,815,500 7,366,320 Deposits from customers 1,404,409 1,432,529 Taxes payable 2,936,992 160,081 Due to related parties 336,072 56,273 -------------- -------------- Total current liabilities 19,159,602 15,336,868 -------------- -------------- OTHER LIABILITIES: Deferred government grant 396,250 393,500 Warrant/purchase option liability 21,000 43,400 -------------- -------------- Total other liabilities 417,250 436,900 -------------- -------------- Total liabilities 19,576,852 15,773,768 -------------- -------------- COMMITMENTS AND CONTINGENCIES SHAREHOLDERS’ EQUITY Preferred stock, $0.001 par value, 50,000,000 shares authorized. No Series “A” shares authorized. 48,000,000 Series “B” shares authorized. No Series “B” shares issued and outstanding - - Common stock, $0.001 par value, 40,000,000 shares authorized, 7,604,800 and 7,161,919 shares issued and outstanding as of June 30, 2012 (Unaudited) and December 31, 2011 7,605 7,162 Paid-in capital 37,021,085 35,784,378 Statutory reserves 5,708,135 5,708,135 Retained earnings 42,095,651 38,492,031 Accumulated other comprehensive income 8,793,579 8,111,107 -------------- -------------- Total shareholders’ equity 93,626,055 88,102,813 -------------- -------------- Total liabilities and shareholders’ equity $ 113,202,907 $ 103,876,581 ============== ============== SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2012 AND 2011 (Unaudited) For Three Months Ended For Six Months Ended June 30, June 30, ----------------------- ----------------------- 2012 2011 2012 2011 ----------- ----------- ----------- ----------- REVENUE, NET $ 8,870,848 $ 9,096,141 $16,797,185 $16,183,095 COST OF REVENUE 3,746,938 4,637,007 7,390,596 8,128,353 ----------- ----------- ----------- ----------- GROSS PROFIT 5,123,910 4,459,134 9,406,589 8,054,742 ----------- ----------- ----------- ----------- OPERATING EXPENSES: Research and development 330,532 1,801,551 334,186 2,089,023 Selling expenses 670,567 609,826 1,376,183 979,230 General and administrative 1,834,280 515,293 2,939,715 1,810,091 ----------- ----------- ----------- ----------- Total operating expenses 2,835,379 2,926,670 4,650,084 4,878,344 ----------- ----------- ----------- ----------- INCOME FROM OPERATIONS 2,288,531 1,532,464 4,756,505 3,176,398 ----------- ----------- ----------- ----------- OTHER INCOME (EXPENSE): Other income (expense), net 2,238 (4,549) 55,998 (4,367) Interest income (expense), net (25,929) (98,973) (179,541) (69,301) Change in fair value of warrant/purchase option liability 16,800 360,153 22,400 1,095,647 ----------- ----------- ----------- ----------- Total other income (expense), net (6,891) 256,631 (101,143) 1,021,979 ----------- ----------- ----------- ----------- INCOME BEFORE PROVISION FOR INCOME TAXES 2,281,640 1,789,095 4,655,362 4,198,377 PROVISION FOR INCOME TAXES 582,774 281,705 1,051,742 759,155 ----------- ----------- ----------- ----------- NET INCOME 1,698,866 1,507,390 3,603,620 3,439,222 OTHER COMPREHENSIVE INCOME Foreign currency translation adjustment 123,715 1,130,579 682,472 1,596,172 ----------- ----------- ----------- ----------- COMPREHENSIVE INCOME $ 1,822,581 $ 2,637,969 $ 4,286,092 $ 5,035,394 =========== =========== =========== =========== EARNINGS PER SHARE: Basic $ 0.23 $ 0.21 $ 0.48 $ 0.48 =========== =========== =========== =========== Diluted $ 0.23 $ 0.21 $ 0.48 $ 0.48 =========== =========== =========== =========== WEIGHTED AVERAGE NUMBER OF COMMON SHARES: Basic 7,461,227 7,169,419 7,454,837 7,168,176 =========== =========== =========== =========== Diluted 7,461,227 7,169,419 7,454,837 7,174,888 =========== =========== =========== =========== SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED JUNE 30, 2012 AND 2011 (Unaudited) Six months ended June 30, ---------------------------- 2012 2011 ------------- ------------- CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 3,603,620 $ 3,439,222 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation 635,856 498,760 Amortization 200,570 385,722 Provision for doubtful accounts 101,246 - Change in fair value of warrant/purchase option liability (22,400) (1,095,647) Common stock to be issued to related parties for compensation - 26,525 Common stock issued under 2010 stock incentive plan 1,037,911 - Change in operating assets and liabilities Accounts receivable (7,381,238) 1,085,951 Inventories 1,678,678 (8,711,510) Deposits, prepaid expenses and other receivables 649,485 (919,717) Prepayments for raw materials purchasing (7,121,001) 1,654,995 Accounts payable 1,614,377 577,915 Other payables and accrued expenses 99,033 (449,155) Deposits from customers (38,170) 286,977 Taxes payable 2,778,594 (702,883) ------------- ------------- Net cash used in operating activities (2,163,439) (3,922,845) ------------- ------------- CASH FLOWS FROM INVESTING ACTIVITIES: Payments of long-term prepayments (349,464) (307,642) Refund of long-term prepayments 475,980 - Loan to third parties (1,942,963) (2,847,846) Collection of loan to third parties - 8,871,193 Purchases of property, plant and equipment (127,531) (46,186) Purchases of intangible assets - (51,222) Payments on construction-in-progress (79,806) (4,013,980) ------------- ------------- Net cash (used in) provided by investing activities (2,023,784) 1,604,317 ------------- ------------- CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from short-term loans 63,464 1,724,019 Repayment of short-term loans (666,372) (612,440) Repayment of government grants (317,320) - Due to related parties 280,901 190,630 ------------- ------------- Net cash (used in) provided by financing activities (639,327) 1,302,209 ------------- ------------- EFFECT OF EXCHANGE RATE CHANGES ON CASH 119,563 174,990 ------------- ------------- DECREASE IN CASH (4,706,987) (841,329) CASH, beginning of period 7,048,968 5,887,831 ------------- ------------- CASH, end of period $ 2,341,981 $ 5,046,502 ============= ============= SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest $ 309,010 $ 119,128 ============= ============= Cash paid for income taxes $ 88,054 $ 1,262,699 ============= ============= Non-cash investing and financing activities Long-term prepayment transferred to construction-in-progress $ 666,372 $ 571,692 ============= ============= Construction-in-progress transferred to property, plant and equipment $ 3,630 $ - ============= ============= Share issued to settle payables to related parties $ 199,239 $ - ============= ============= SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY (UNAUDITED) Common stock ----------------- Paid-in Shares Amount capital --------- ------- ------------ BALANCE, December 31, 2011 7,161,919 $ 7,162 $ 35,784,378 Share issued under 2010 stock incentive plan 442,881 443 1,236,707 Foreign currency translation - - - Net income - - - --------- ------- ------------ BALANCE, June 30, 2012 7,604,800 $ 7,605 $ 37,021,085 ========= ======= ============ Retained earnings ----------------------- Accumulated other Statutory comprehensive reserves Unrestricted income Total ---------- ------------ ------------- ----------- BALANCE, December 31, 2011 $5,708,135 $ 38,492,031 $ 8,111,107 $88,102,813 Share issued under 2010 stock incentive plan - - - 1,237,150 Foreign currency translation - - 682,472 682,472 Net income - 3,603,620 - 3,603,620 ---------- ------------ ------------- ----------- BALANCE, June 30, 2012 $5,708,135 $ 42,095,651 $ 8,793,579 $93,626,055 ========== ==
